Hutchison China Meditech Limited Block Admission Application (5019U)
July 30 2020 - 1:00AM
UK Regulatory
TIDMHCM
RNS Number : 5019U
Hutchison China Meditech Limited
30 July 2020
Block Admission Application
London: Thursday, July 30, 2020: Hutchison China MediTech
Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announces an
application has been made to the London Stock Exchange plc for a
block admission of 30,221,458 ordinary shares, par value of US$0.10
each ("Ordinary Shares") to be admitted to trading on AIM. It is
expected that such admission will become effective on August 4,
2020.
These Ordinary Shares will be issued from time to time pursuant
to the exercise of share options under the Share Option Scheme
conditionally adopted by Chi-Med in 2015 ("2015 Share Option
Scheme"). When issued, these Ordinary Shares will be credited as
fully paid and will rank pari passu with the existing Ordinary
Shares in issue. Chi-Med is seeking this block admission due to the
recent refreshment of the limits of the 2015 Share Option Scheme,
as approved at Chi-Med's annual general meeting held on April 27,
2020 ("AGM"), whereby Chi-Med was empowered to grant further
options under that scheme in respect of a maximum of 34,528,738
Ordinary Shares. Under the existing block admission facility for
the 2015 Share Option Scheme, the unutilised balance covers
23,130,970 Ordinary Shares. Of this remaining balance, 18,823,690
Ordinary Shares are reserved for the exercise of options already
granted under the 2015 Share Option Scheme. Therefore, only
4,307,280 Ordinary Shares of the remaining balance under the
existing block admission facility could be utilised with respect to
share options to be granted under the 2015 Share Option Scheme as
refreshed at the AGM. Following admission, the Company's total
issued share capital remains unchanged at 710,574,765 Ordinary
Shares, with each share carrying one right to vote and with no
shares held in treasury. The Company will make six-monthly
announcements of the utilisation of the block admission, in line
with its obligations under AIM Rule 29 and monthly announcements as
to any changes to its total voting rights.
About Chi-Med
Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage,
biopharmaceutical company committed, over the past twenty years, to
the discovery and global development of targeted therapies and
immunotherapies for the treatment of cancer and immunological
diseases. It has a portfolio of nine cancer drug candidates
currently in clinical studies around the world and extensive
commercial infrastructure in its home market of China. For more
information, please visit: www.chi-med.com .
Forward Looking Statements
This announcement contains forward-looking statements within the
meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements involve risks and uncertainties. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see
Chi-Med's filings with the U.S. Securities and Exchange Commission
and on AIM. Chi-Med undertakes no obligation to update or revise
the information contained in this announcement, whether as a result
of new information, future events or circumstances or
otherwise.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
Media Enquiries
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Europe - Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779
545 055 (Mobile)
Chi-Med@fticonsulting.com
Asia - Joseph Chi Lo / Zhou Yi, Brunswick +852 9850 5033 (Mobile), jlo@brunswickgroup.com /
+852 97 83 6894 (Mobile), y zhou@brunswickgroup.com
Nominated Advisor
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK)
Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ALSDZGZNMLVGGZM
(END) Dow Jones Newswires
July 30, 2020 02:00 ET (06:00 GMT)
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Apr 2023 to Apr 2024